Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Waiting for the verdict

All eyes will be on Celltech as the London Stock Exchange opens for business on Monday, the first day it will trade as a FTSE 100 company. The LSE was closed when an FDA advisory committee on Friday recommended a limited label for CCH's Mylotarg gemtuzumab zogamicin in acute myeloid leukemia (AML), which was presented to the panel by partner Wyeth-Ayerst. Rumors that the product had been rejected prompted a halt in trading of the company's ADRs on the New York Stock Exchange at $36.375, down $4.125 on the day. CCH closed Friday at 1307.5p, up 72.5p on the day, but down 470p on the week at a market cap of £10.4 billion ($16.4 billion). (see Regulation, A6).

Private rounds

AdProTech raised £5 million ($7.9 million) in a second funding round. The autoimmune and inflammation company will use the funds to move APT070, a

Read the full 1420 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers